Valneva SE | Cash Flow

Fiscal year is January-December. All values EUR Thousands.
2013
2014
2015
2016
2017
2018
Net Income before Extraordinaries
24,110.00
26,272.00
20,617.00
49,184.00
11,482.00
3,264
Depreciation, Depletion & Amortization
9,056.00
12,359.00
11,442.00
11,269.00
11,141.00
6,828
Other Funds
2,206.00
412.00
441.00
33,746.00
5,747.00
1,728
Funds from Operations
17,260.00
13,501.00
9,616.00
4,169.00
3,722.00
8,364
Changes in Working Capital
3,311.00
938.00
14,585.00
3,032.00
4,199.00
3,955
Net Operating Cash Flow
20,571.00
14,439.00
24,201.00
1,137.00
7,921.00
12,319
Capital Expenditures
3,274.00
3,738.00
2,646.00
3,682.00
4,038.00
Sale of Fixed Assets & Businesses
14,760.00
1,712.00
128.00
15,280.00
-
Purchase/Sale of Investments
10,037.00
3,514.00
1,999.00
-
94.00
Net Investing Cash Flow
21,523.00
1,488.00
26,698.00
11,598.00
4,132.00
Issuance/Reduction of Debt, Net
2,247.00
3,427.00
22,122.00
23,333.00
5,311.00
Net Financing Cash Flow
34,689.00
5,274.00
64,195.00
15,860.00
5,458.00
Net Change in Cash
35,677.00
7,652.00
13,050.00
6,640.00
1,722.00
Free Cash Flow
21,946.00
15,385.00
26,055.00
2,895.00
5,031.00
Deferred Taxes & Investment Tax Credit
-
-
-
-
1,684.00
-
Net Assets from Acquisitions
-
-
22,181.00
-
-
Change in Capital Stock
36,936.00
8,701.00
42,073.00
7,473.00
147.00
Exchange Rate Effect
36.00
25.00
246.00
1,241.00
53.00

About Valneva SE

View Profile
Address
Campus Bio-Ouest 6
Saint-Herblain Lorraine 44800
France
Employees -
Website http://www.valneva.com
Updated 07/08/2019
Valneva SE is a biotech company which engages in the development, production, and marketing of vaccine and preventive medicine. It operates through the following segments: Commercialized Vaccines, Technologies and Services, and Vaccine Candidates. The Commercialized Vaccines segment includes currently marketed vaccines of the group such as JEV and DUKORAL.